ARTICLES BY LOUIS

• Platform Or Perish: 9 Steps To Better Partnerships

  7/28/2017

  Companies in every industry are defining their next generation of value chains. In doing so, they are increasingly integrating with third parties, and their platforms. Savvy leaders leverage these relationships to unlock their next waves of strategic growth. Here are 9 steps to move the process forward, based on a new report from Accenture. 

• You Decide: Technologies Impacting Drug Development And Manufacturing

  7/20/2017

  Quickly: What three technologies impact your drug development and manufacturing? How do those technologies impact your outsourcing partners, processes, and decisions? Thanks for joining today’s flash mind exercise. You’ve also joined executives on the Outsourced Pharma Editorial Advisory Board who did the same. Let’s compare.

• New Report Helps Forecast Next 5 Years Of Outsourcing

  7/11/2017

  Discerning growth opportunities (or business contractions) in the drug development and manufacturing outsourcing space is a challenging exercise. Among other things, it requires reading between the lines of various industry reports concentrating otherwise, for example on comparing commercial product sales and R&D pipelines. An “otherwise” focused report worth our attention is the EvaluatePharma World Preview 2017, Outlook to 2022. 

• Channeling Socrates With The FDA On Innovative Technologies

  7/5/2017

  Paraphrasing Henry Hoppe of Xenetic Bioscience, companies on the bleeding edge of innovative technology in drug development and manufacturing should treat visits to the FDA more like Socratic dialogues than stressful duels. Mark Butchko, who’s charted over a decade with Lilly, advises holding some of those dialogues during “pre-operational visits,” or POVs.

• New Board Members: Co-Creating, Energized, And Positively Provocative

  6/28/2017

  It’s halftime on 2017. Summer has officially arrived. Can you believe it? A perfect time to … add veteran industry professionals to our organization. Outsourced Pharma is pleased to announce three new Editorial Advisory Board members, from Merck, Eli Lilly, and Tunnell Consulting. Read what they have to say about our industry to this point, and our future.

• The Less And More In Biogen's Supply Chain

  6/26/2017

  Consolidate by (a) providing trusted partners more opportunity, and (b) initiating fewer new relationships except where technology-critical. Also: look for innovation at experienced providers, while the less inured work to gain your trust. So say three Biogen executives. Here are the details.

• Japan And The Art Of Supply-Chain Specialization

  6/12/2017

  So you say you’re a specialist. And that’s probably a good thing. But consider this paradox: The best “specialists” are also solid “generalists.” I’m reminded of this contrarian concept by a recent visit to Japan, where I originally learned it, and the ongoing debate at Outsourced Pharma conferences regarding partnerships in the external supply chain.   

• Instant Innovation In The Supply Chain

  6/1/2017

  In our second part on supply chain innovation, executives at Biogen and Merck discuss the drug industry’s engagement with “instant innovation,” and a bottom up approach to cultural change.

• Risk And Small “i” Innovation In Pharma Outsourcing

  5/26/2017

  Innovation brings risk. Pharma is risk averse. Therefore, we have less innovation than in other industries. Most likely you’ve heard it all before. But is it valid? We talk to executives from Biogen, Merck, and Sanofi Biologics to find out. 

• Pharma's Whole-Brained Sourcing Leaders

  5/22/2017

  Today in Pharma, procurement and sourcing leaders need to be whole-brained. Left-side and right-side skills and talents have become equally important in these outsourcing activities. Are we pointing to the two sides of human intellect as perfected in procurement? Well, yes, and here’s the explanation from Pharma’s sourcing leaders themselves.